Prescribing information is available here. Adverse Event reporting can be found in the footer.
Binosto®
Binosto® is a buffered, soluble, effervescent alendronate tablet formulation that addresses the challenges of gastrointestinal (GI) tolerability and patient adherence to bisphosphonates1-3
While oral bisphosphonates have broad-spectrum efficacy to reduce fragility fractures, persistence is crucial.3,4 2 in 3 postmenopausal women in the UK discontinue oral bisphosphonate therapy within a year.5
Binosto® is indicated for the treatment of postmenopausal osteoporosis. It reduces the risk of vertebral and hip fractures.1
Fully soluble, buffered, Binosto® enhances upper GI tolerability, supporting persistence.2,3
 |
Avoids solid bisphosphonate irritating the oesophageal mucosa6,7
Gastric pH levels are rapidly buffered to >3, lessening the risk of damage if reflux occurs6,7 |
 |
Fewer patients discontinued treatment due to GI adverse events with Binosto® than with conventional alendronate tablets3 |
 |
Significantly increased persistence vs conventional alendronate tablets3 |
 |
Persistence rate of 81% reported in real-world patients at 1 year3 |
 |
Dissolves in just half a glass of plain water (120 ml)1 |
Patient Guide download
Please register for an instant download of the Binosto® Patient Guide. The guide will provide more information for patients on Binosto®, how to take it, osteoporosis and tips on how to manage their condition.
References
- Binosto® 70 mg Effervescent Tablets Summary of Product Characteristics. Available at: https://www.medicines.org.uk/emc/product/7113. Accessed: December 2025.
- Minisola S et al. JBMR Plus 2021; 5(7): e10510.
- Giusti A et al. Aging Clin Exp Res 2021; 33(9): 2529-37.
- Bastounis A et al. Osteoporos Int 2022; 33(6): 1223-33.
- Morley J et al. Osteoporos Int 2020; 31(3): 533-45.
- Fuggle N et al. Aging Clin Exp Res 2022; 34(11): 2625-34.
- Hodges LA et al. Int J Pharm 2012; 432(1-2): 57-62.
Information
For information on our products please visit EMC, https://www.medicines.org.uk/emc/ and search the product for a Summary of Product Characteristics
Adverse events should be reported. Reporting forms and information can be found at yellowcard.mhra.gov.uk or search for MHRA Yellow Card in the Google Play or Apple App Store. Adverse events should also be reported to Thornton and Ross Limited by emailing thorntonross@medinformation.co.uk or by calling 01484 848164.
UK-MULT-130c(4) | December 2025